N-glycomic profiling of colorectal cancer according to tumor stage and location.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Glycomics*; Biomarkers, Tumor/*analysis ; Colorectal Neoplasms/*metabolism ; Polysaccharides/*analysis; Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/metabolism ; Colon/pathology ; Colorectal Neoplasms/pathology ; Disease Progression ; Female ; Glycosylation ; Humans ; Infant ; Male ; Middle Aged ; Neoplasm Staging ; Polysaccharides/metabolism ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization ; Young Adult

Alterations in glycosylation are seen in many types of cancer, including colorectal cancer (CRC). Glycans, the sugar moieties of glycoconjugates, are involved in many important functions relevant to cancer and can be of value as biomarkers. In this study, we have used mass spectrometry to analyze the N-glycan profiles of 35 CRC tissue samples and 10 healthy tissue samples from non-CRC patients who underwent operations for other reasons. The tumor samples were divided into groups depending on tumor location (right or left colon) and stage (II or III), while the healthy samples were divided into right or left colon. The levels of neutral and acidic N-glycan compositions and glycan classes were analyzed in a total of ten different groups. Surprisingly, there were no significant differences in glycan levels when all right- and left-sided CRC samples were compared, and few differences (such as in the abundance of the neutral N-glycan H3N5) were seen when the samples were divided according to both location and stage. Multiple significant differences were found in the levels of glycans and glycan classes when stage II and III samples were compared, and these glycans could be of value as candidates for new markers of cancer progression. In order to validate our findings, we analyzed healthy tissue samples from the right and left colon and found no significant differences in the levels of any of the glycans analyzed, confirming that our findings when comparing CRC samples from the right and left colon are not due to normal variations in the levels of glycans between the healthy right and left colon. Additionally, the levels of the acidic glycans H4N3F1P1, H5N4F1P1, and S1H5N4F1 were found to change in a cancer-specific but colon location-nonspecific manner, indicating that CRC affects glycan levels in similar ways regardless of tumor location.
Competing Interests: Authors Annamari Heiskanen and Tero Satomaa are employed by the company Glykos Finland Ltd. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Nat Rev Immunol. 2008 Nov;8(11):874-87. (PMID: 18846099)
Nat Rev Drug Discov. 2005 Jun;4(6):477-88. (PMID: 15931257)
Sci Rep. 2018 Jun 5;8(1):8655. (PMID: 29872119)
Proteomics. 2018 Feb;18(3-4):. (PMID: 29316255)
Mol Cancer. 2018 Dec 21;17(1):177. (PMID: 30577807)
Mol Cell Proteomics. 2015 Feb;14(2):277-88. (PMID: 25452313)
J Clin Oncol. 2004 Aug 15;22(16):3408-19. (PMID: 15199089)
Cancer Sci. 2013 Jan;104(1):135-41. (PMID: 23004678)
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450. (PMID: 30395289)
Mol Cell Proteomics. 2018 Nov;17(11):2107-2118. (PMID: 30072579)
Gut Liver. 2013 Nov;7(6):629-41. (PMID: 24312702)
J Clin Endocrinol Metab. 2017 Nov 1;102(11):3990-4000. (PMID: 28938401)
BMC Cell Biol. 2009 Jun 02;10:42. (PMID: 19490625)
Nucleic Acids Res. 2017 Jan 4;45(D1):D1100-D1106. (PMID: 27924013)
Int J Cancer. 2002 Oct 10;101(5):403-8. (PMID: 12216066)
J Proteome Res. 2015 Aug 7;14(8):3322-35. (PMID: 26088811)
Clin Chim Acta. 2018 Dec;487:357-362. (PMID: 30296444)
J Proteome Res. 2014 Jan 3;13(1):277-88. (PMID: 24295106)
Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907. (PMID: 20647400)
J Proteome Res. 2014 Nov 7;13(11):4910-8. (PMID: 25096929)
Gut. 2017 Apr;66(4):683-691. (PMID: 26818619)
Cancer. 2012 Feb 1;118(3):639-50. (PMID: 21853445)
Anticancer Res. 2011 Jun;31(6):2191-5. (PMID: 21737640)
Acta Histochem. 2011 May;113(3):236-47. (PMID: 20199800)
Mol Cell Proteomics. 2016 Jan;15(1):124-40. (PMID: 26537799)
Nat Rev Cancer. 2015 Sep;15(9):540-55. (PMID: 26289314)
Eur J Surg Oncol. 2015 Mar;41(3):300-8. (PMID: 25468456)
Glycobiology. 2015 Oct;25(10):1064-78. (PMID: 26085185)
Oncotarget. 2018 Jul 17;9(55):30610-30623. (PMID: 30093973)
J Proteome Res. 2005 Jul-Aug;4(4):1073-85. (PMID: 16083256)
Tumour Biol. 2000 May-Jun;21(3):153-64. (PMID: 10754466)
Acc Chem Res. 2016 Oct 18;49(10):2099-2106. (PMID: 27653471)
Curr Treat Options Oncol. 2018 May 23;19(6):31. (PMID: 29796712)
Dis Colon Rectum. 2010 Jan;53(1):57-64. (PMID: 20010352)
Cancer. 1995 Sep 1;76(5):727-35. (PMID: 8625173)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
J Proteome Res. 2008 Apr;7(4):1693-703. (PMID: 18311904)
Mol Cell Proteomics. 2012 Sep;11(9):571-85. (PMID: 22573871)
Nat Rev Cancer. 2005 Jul;5(7):526-42. (PMID: 16069816)
Cancer Res. 2009 Jul 15;69(14):5811-9. (PMID: 19584298)

0 (Biomarkers, Tumor)
0 (Polysaccharides)

Date Created: 20200630 Date Completed: 20200909 Latest Revision: 20200909

20240105

PMC7323945

10.1371/journal.pone.0234989

32598367